A Phase 3 interventional study of Cilta-cel and Pomalidomide in Multiple Myeloma, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 88 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing ciltacabtagene autoleucel in Multiple Myeloma — 3 open to participants now, 7 under way, 1 of them phase 3. ciltacabtagene autoleucel · Multiple Myeloma.
Among the 10 studies testing ciltacabtagene autoleucel in Multiple Myeloma, this one has the largest enrollment, is the only one that started in 2020, is the only one in phase 3, and was the 4th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →3 of the 10 studies testing ciltacabtagene autoleucel in Multiple Myeloma are open now, in 8 countries. Recruiting first, the newest first:
Medical College of Wisconsin · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Belgium, China and 5 more countries
Ages 18+
By country, each count listing its studies:
ciltacabtagene autoleucel: first FDA approval 2022 (Carvykti), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 1 · Phase 4 1
First in 2018; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 419 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 105 across the 10 interventional studies. Of the 3 that completed or were terminated, 2 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 10 have an industry lead sponsor. The 6 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
126 studies in Multiple Myeloma by Johnson & Johnson: 13 open now, 33 under way, 12 of them phase 3. Of 82 finished, 33 (40%) have results posted.
Among the 126 studies in Multiple Myeloma by Johnson & Johnson, this one is the 17th largest by enrollment of the 100 interventional ones that give a count, is one of 3 that started in 2020, is one of 35 in phase 3, reaches primary completion later than 0 of the 32 other live ones, and was the 87th registered.
Johnson & Johnson’s Multiple Myeloma studies by the year they started, since 1995.
3 of the studies testing ciltacabtagene autoleucel in Multiple Myeloma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04133636Janssen Research & Development, LLCA Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma | 2027-02-26 |
| NCT06623630Washington University School of MedicineLymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function | 2027-06-30 |
| NCT07093554Medical College of WisconsinCilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma | 2027-07-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies testing ciltacabtagene autoleucel in Multiple Myeloma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 126 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy of ciltacabtagene autoleucel (cilta-cel) with standard therapy, either Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have clinical laboratory values meeting the following criteria during the Screening Phase (re testing is allowed but the below criteria must be met in the latest test prior to randomization):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive either PVd or DPd as a standard therapy. In PVd treatment, participants will receive oral pomalidomide 4 mg on Days 1 to 14 in each cycle; bortezomib 1.3 mg/meter square (m\^2) SC on Days 1, 4, 8 and 11 (Cycles 1 to 8) and on Days 1 and 8 (Cycle 9 onwards) and oral dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 (Cycles 1 to 8) and Days 1, 2, 8 and 9 (Cycle 9 onwards). Each cycle will consist of 21 days. In DPd treatment, participants will receive daratumumab SC 1800 mg weekly on Days 1, 8, 15, and 22 (Cycles 1 and 2), every 2 weeks on Days 1 and 15 (Cycles 3 to 6) and every 4 weeks on Day 1 (Cycle 7 onwards); oral pomalidomide 4 mg on Days 1 to 21 (Cycle 1 onwards); dexamethasone 40 mg oral or IV weekly on Days 1, 8, 15, and 22 (Cycle 1 onwards). Each cycle will consist of 28 days. Participants will continue to receive PVd or DPd until confirmed PD, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs earlier.
Drug: Pomalidomide · Drug: Bortezomib · Drug: Dexamethasone · Drug: Daratumumab
Participants will receive at least one cycle of bridging therapy (PVd or DPd) and additional cycles of bridging therapy may be considered based on participant's clinical status and timing of availability of cilta-cel along with conditioning regimen (cyclophosphamide 300 milligram \[mg\]/m\^2 intravenous \[IV\] and fludarabine 30 mg/m\^2 IV daily, for 3 days), and cilta-cel infusion 0.75 \* 10\^6 chimeric antigen receptor (CAR)-positive viable T cells/ kilogram (kg).
Drug: Cilta-cel
Cilta-cel infusion will be administered at a target dose of 0.75 \* 10\^6 CAR-positive viable T cells/kilogram (kg).
Pomalidomide 4 mg will be administered orally.
Bortezomib 1.3 milligram per meter square (mg/m\^2) will be administered subcutaneously (SC).
Dexamethasone 20 mg/day (10mg/day for participants \>75 years of age) (on bortezomib treatment days and the days following bortezomib treatment) will be administered orally in PVd treatment; and orally or intravenous (IV) at 40 mg weekly (20mg weekly for participants \>75 years of age) in DPd treatment.
Daratumumab 1800 mg will be administered SC.
Progression Free Survival (PFS)
PFS: defined as time from date of randomization to date of first documented progressed disease (PD) as per International Myeloma Working Group (IMWG) criteria, or death due to any cause, whichever occurred first. PD: increase of 25% from lowest response value: serum and urine M-component (absolute increase must be \>=0.5 grams per deciliter \[g/dL\] and \>=200 milligrams \[mg\] per 24 hours, respectively); only in participants without measurable serum and urine M-protein levels, difference between involved and uninvolved free light chain (FLC) levels (absolute increase of \>10 mg/dL); only in participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow plasma cell (PC)% (absolute increase of \>=10%), appearance of new lesion; definite development of new bone lesions or definite increase in size of existing bone lesions, \>=50% increase in circulating PCs (minimum of 200 cells per microliter \[uL\]) if this was only measure of disease.
Time frame: From randomization (Day 1) to either progressive disease or death, whichever occurred first (up to 3.9 years)
Percentage of Participants Who Achieved Complete Response (CR) or Stringent Complete Response (sCR)
Time frame: From randomization (Day 1) up to 7 years
Percentage of Participants Who Achieved Overall Minimal Residual Disease (MRD) Negative Status (at 10^-5)
Time frame: From randomization (Day 1) up to 7 years
Percentage of Participants Who Were in CR or sCR and Achieved MRD-negative Status at 12 Months +/-3 Months
Time frame: From randomization (Day 1) up to 12 months +/- 3 months
Percentage of Participants Who Achieved Sustained MRD-negative Status
Time frame: From randomization (Day 1) up to 7 years
Overall Survival (OS)
Time frame: From randomization (Day 1) up to 7 years
Time to Worsening of Symptoms Using the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Total Symptom Score
Time frame: From randomization (Day 1) up to 7 years
Overall Response Rate (ORR)
Time frame: From randomization (Day 1) up to 7 years
Progression Free Survival on Next-line Therapy (PFS2)
Time frame: From randomization (Day 1) up to 7 years
Number of Participants With Treatment-emergent Adverse Events (AEs)
Time frame: From Cycle 1 Day 1 up to 7 years
Number of Participants With Treatment-emergent Adverse Events (AEs) by Severity
Time frame: From Cycle 1 Day 1 up to 7 years
Change From Baseline in Systemic Cytokine Concentrations on Participants Who Received Cilta-cel as Study Treatment (Arm B)
Time frame: From baseline (Cycle 1 Day 1) up to 7 years
Change From Baseline in Levels of CAR-T Cell Activation Markers on Participants Who Received Cilta-cel as Study Treatment (Arm B)
Time frame: From baseline (Cycle 1 Day 1) up to 7 years (each cycle of 28 days)
Change From Baseline in Levels of JNJ-68284528 T Cell Expansion (Proliferation), and Persistence on Participants Who Received Cilta-cel as Study Treatment (Arm B)
Time frame: From baseline (Cycle 1 Day 1) up to 7 years (each cycle of 28 days)
Number of Participants With Anti-JNJ-68284528 Antibodies on Participants Who Received Cilta-cel as Study Treatment (Arm B)
Time frame: From Cycle 1 Day 1 up to 7 years
Change From Baseline in Health-Related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 Item (EORTC-QLQ-C30) Scale Score
Time frame: From baseline (Cycle 1 Day 1) up to 7 years (each cycle of 28 days)
Change From Baseline in Health-Related Quality of Life as Assessed by MySIm-Q Scale Sore
Time frame: From baseline (Cycle 1 Day 1) up to 7 years (each cycle of 28 days)
Change From Baseline in Health-Related Quality of Life as Assessed by European Quality of Life - 5 Dimensions-5 Levels (EQ-5D-5L) Questionnaire Scale Score
Time frame: From baseline (Cycle 1 Day 1) up to 7 years (each cycle of 28 days)
Change From Baseline in Health-Related Quality of Life as Assessed by Patient Global Impression of Symptom Severity (PGIS) Scale Score
Time frame: From baseline (Cycle 1 Day 1) up to 7 years (each cycle of 28 days)
Number of Participants in Health-Related Quality of Life as Assessed by The Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item
Time frame: From randomization (Day 1) up to 7 years
| Milestone | Arm A: Standard Therapy: PVd or DPd | Arm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel]) |
|---|---|---|
| Started | 211 | 208 |
| Treated (safety analysis set) | 208 | 208 |
| Completed | 0 | 0 |
| Not completed | 211 | 208 |
| Withdrew: Ongoing | 124 | 157 |
| Withdrew: Death | 82 | 50 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 5 | 0 |
PFS: defined as time from date of randomization to date of first documented progressed disease (PD) as per International Myeloma Working Group (IMWG) criteria, or death due to any cause, whichever occurred first. PD: increase of 25% from lowest response value: serum and urine M-component (absolute increase must be \>=0.5 grams per deciliter \[g/dL\] and \>=200 milligrams \[mg\] per 24 hours, respectively); only in participants without measurable serum and urine M-protein levels, difference between involved and uninvolved free light chain (FLC) levels (absolute increase of \>10 mg/dL); only in participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow plasma cell (PC)% (absolute increase of \>=10%), appearance of new lesion; definite development of new bone lesions or definite increase in size of existing bone lesions, \>=50% increase in circulating PCs (minimum of 200 cells per microliter \[uL\]) if this was only measure of disease.
| months | Arm A: Standard Therapy: PVd or DPd | Arm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel]) |
|---|---|---|
| Progression Free Survival (PFS) | 11.79 (9.66 to 14.00) | NA (34.50 to NA) |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over All-cause mortality: From randomization (Day 1) up to 3.9 years; SAEs/Other AEs: Arm A: From Cycle 1 Day 1 up to 45 months; Arm B: From Cycle 1 Day 1 up to 8 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Standard Therapy: PVd or DPd | 83/211 (39.3%) | 98/208 (47.1%) | 207/208 (99.5%) |
| Arm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel]) | 50/208 (24%) | 98/208 (47.1%) | 208/208 (100%) |
| Event | Arm A: Standard Therapy: PVd or DPd | Arm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel]) |
|---|---|---|
| PneumoniaInfections and infestations | 14/208 | 8/208 |
| Covid-19 PneumoniaInfections and infestations | 12/208 | 12/208 |
| Facial ParalysisNervous system disorders | 1/208 | 9/208 |
| Cytokine Release SyndromeImmune system disorders | 1/208 | 7/208 |
| Covid-19Infections and infestations | 7/208 | 6/208 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 6/208 | 5/208 |
| DiarrhoeaGastrointestinal disorders | 0/208 | 5/208 |
| PyrexiaGeneral disorders | 5/208 | 4/208 |
| Pneumocystis Jirovecii PneumoniaInfections and infestations | 5/208 | 1/208 |
| Upper Respiratory Tract InfectionInfections and infestations | 5/208 | 4/208 |
| Event | Arm A: Standard Therapy: PVd or DPd | Arm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel]) |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 178/208 | 187/208 |
| Cytokine Release SyndromeImmune system disorders | 0/208 | 129/208 |
| ThrombocytopeniaBlood and lymphatic system disorders | 67/208 | 113/208 |
| AnaemiaBlood and lymphatic system disorders | 57/208 | 110/208 |
| NauseaGastrointestinal disorders | 43/208 | 101/208 |
| HypogammaglobulinaemiaImmune system disorders | 18/208 | 94/208 |
| FatigueGeneral disorders | 70/208 | 60/208 |
| DiarrhoeaGastrointestinal disorders | 65/208 | 69/208 |
| Covid-19Infections and infestations | 61/208 | 16/208 |
| HeadacheNervous system disorders | 27/208 | 55/208 |
| Age, Continuous(Years) | Arm A: Standard Therapy: PVd or DPd | Arm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel]) | Total |
|---|---|---|---|
| Mean | 60.4 ± 9.09 | 59.7 ± 10.09 | 60.1 ± 9.6 |
| Sex: Female, Male(Participants) | Arm A: Standard Therapy: PVd or DPd | Arm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel]) | Total |
|---|---|---|---|
| Female | 87 | 92 | 179 |
| Male | 124 | 116 | 240 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Standard Therapy: PVd or DPd | Arm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel]) | Total |
|---|---|---|---|
| Hispanic or Latino | 10 | 18 | 28 |
| Not Hispanic or Latino | 165 | 152 | 317 |
| Unknown or Not Reported | 36 | 38 | 74 |
| Race (NIH/OMB)(Participants) | Arm A: Standard Therapy: PVd or DPd | Arm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel]) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 20 | 16 | 36 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 7 | 6 | 13 |
| White | 157 | 157 | 314 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 26 | 28 | 54 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · innovativemedicine.jnj.com
Ran from Jun 2020 to primary completion in May 2024, 46 months.
Results were first posted in May 2025, 1 year after primary completion.
Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 46 months is close to that.
Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ciltacabtagene autoleucel · Pomalidomide · Bortezomib · Dexamethasone · Daratumumab
Janssen Research & Development, LLC →